Strumento inattivo

Altre lingue Ocera Therapeutics Inc

Azioni

US67552A1088

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®	20/10/17
Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017	23/08/17
Ocera Therapeutics Reports Second Quarter 2017 Financial Results	01/08/17
Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis	01/06/17
Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, June 2	26/05/17
Ocera Therapeutics : Biotech Stocks Under Scanner -- Bioverativ, Zosano Pharma, MannKind, and Ocera Therapeutics	10/05/17
Ocera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical Update	09/05/17
Ocera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 2017	03/05/17
Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)	12/04/17
Ocera to Present at the 16th Annual Needham Healthcare Conference	27/03/17
Ocera Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update	10/03/17
Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy	08/03/17
Ocera to Present at the Cowen and Company 37th Annual Healthcare Conference	28/02/17
Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy	30/01/17
Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis	05/01/17
Ocera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with Hepatic Encephalopathy	07/12/16
Ocera to Present at the Stifel 2016 Healthcare Conference	09/11/16
Ocera Therapeutics Reports Third Quarter 2016 Financial Results and Company Update	02/11/16
Ocera Therapeutics : Appoints Biopharmaceutical Veteran Willard Dere, M.D. to Board of Directors	28/10/16
Ocera Therapeutics Appoints Biopharmaceutical Veteran Willard Dere, M.D. to Board of Directors	28/10/16

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Ocera Therapeutics Inc

Azioni

US67552A1088

Altre lingue

Filtri